Suzhou Bio-Mingsai Biopharmaceutical

Suzhou Bio-Mingsai Biopharmaceutical is a biotechnology company focused on the discovery and development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. The company utilizes a proprietary site-specific conjugation technology platform designed to produce homogeneous ADCs with enhanced stability and therapeutic efficacy. Its research and development efforts are primarily directed toward solid tumor indications, with a pipeline featuring candidates targeting HER2 and TROP2. Headquartered in the Suzhou Industrial Park, Bio-Mingsai aims to overcome the limitations of traditional ADCs through innovative linker-payload chemistry and protein engineering. The firm is backed by prominent venture capital investors and is led by a team with deep expertise in medicinal chemistry and biologics.